635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
Publication
, Conference
Alcaraz, A; Szmulewitz, RZ; Shore, N; Crawford, ED; Petrylak, DP; Holzbeierlein, J; Villers, A; Azad, AA; Alekseev, B; Iguchi, T; Rosbrook, B ...
Published in: Annals of Oncology
September 2020
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2020
Volume
31
Start / End Page
S523 / S524
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Alcaraz, A., Szmulewitz, R. Z., Shore, N., Crawford, E. D., Petrylak, D. P., Holzbeierlein, J., … Armstrong, A. J. (2020). 635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels. In Annals of Oncology (Vol. 31, pp. S523–S524). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.894
Alcaraz, A., R. Z. Szmulewitz, N. Shore, E. D. Crawford, D. P. Petrylak, J. Holzbeierlein, A. Villers, et al. “635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels.” In Annals of Oncology, 31:S523–24. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.894.
Alcaraz A, Szmulewitz RZ, Shore N, Crawford ED, Petrylak DP, Holzbeierlein J, et al. 635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels. In: Annals of Oncology. Elsevier BV; 2020. p. S523–4.
Alcaraz, A., et al. “635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S523–24. Crossref, doi:10.1016/j.annonc.2020.08.894.
Alcaraz A, Szmulewitz RZ, Shore N, Crawford ED, Petrylak DP, Holzbeierlein J, Villers A, Azad AA, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Sugg J, Haas GP, Stenzl A, Armstrong AJ. 635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels. Annals of Oncology. Elsevier BV; 2020. p. S523–S524.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2020
Volume
31
Start / End Page
S523 / S524
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis